Tumour immunology and cancer immunotherapy

For the doctoral thesis Seminar # 902.218

Program (pdf)

For the doctoral thesis Seminar # 902.218

Coordination:

Prof. Dr. Anna Repic, Prof. Dr. Johannes Huppa, Dr. Philipp Schatzlmaier,
Dr. René Platzer, Prof. Dr. Hannes Stockinger

Topic for the Winter semester 2021/2022:

Tumour immunology and cancer immunotherapy

Venue:

Virtual meeting via Webex
Time: January 31^st - February 1^st, 2022

Day 1: Monday January 31^st:

Meeting: Link
Meeting number (access code): 2734 900 6241,
Meeting password: d7nKGVP5kh7 (37654875 from video systems)

11.00 – 11.15 Coordinators (+ Vladimir Leksa)

Welcome, Introduction to and Overview of the Topic

11.15 – 11.35 Philipp Brunmayr

Hallmarks of cancer, general aspects of cellular transformation, types of cancer (introductory lecture)

11.35 – 11.50 Discussion

11.50 – 12.10 Lena Wagner

Immunosurveillance, immunoediting and tumour evasion mechanisms (plus effects of the tumor on local and systemic immune regulation

12.10 – 12.25 Discussion

12.25 – 12.50 Lunch Break

12.50 – 13.10 Vanessa Mühlgrabner

TILs: what they are, do and recognize

13.10 – 13.25 Discussion

13.25 – 13.45 Angelika Plach

Role of tumor-associated lymphocytes (Treg, Breg) and IgG4 antibodies in cancer progression

13.45 – 14.00 Discussion

14.00 – 14.20 Philipp Schatzlmaier

Inflammaging, chronic infections and cancer

14.20 – 14.35 Discussion

14.35 – 14.55 Gabor Tajti

In the hood - Tumor microenvironment as a way to hide from the immune system (supportive stromal cells, extracellular matrix, tumor vasculature, genetic profile of immune cells within the tumor mass, etc.)

14.55 – 15.10 Discussion

15.10 – 15.30 Malgorzata Kupc

Usability, differences and immunological relevance of various cancer models (cell lines vs. spheroids/organoids vs. ex vivo tumour explants vs. (orthotopic) xenografts in mice spontaneous tumours in mice)

15.30 – 15.45 Discussion

Day 2: Tuesday February 1^st:

Meeting: Link
Meeting number (access code): 2734 763 3118,
Meeting password: VVh3cpJ7Hy4 (88432757 from video systems)

11.00 – 11.20 Anna Repic (+ introduction to day 2)

Role of innate immunity in cancer, tumour-associated myeloid cells with immunosuppressive functions (MDSC, TAM, TAN)

11.20 – 11.35 Discussion

11.35 – 11.55 Romana PRaženicová

Cancer vaccination (peptide- or RNA-based) and ex vivo and in vivo strategies for dendritic cell-based immunotherapy

11.55 – 12.10 Discussion

12.10 – 12.30 René Platzer

Antibody-based therapy in cancer: Immune checkpoint inhibitors, BiTEs, immunoconjugates, ADCC etc.

12.30 – 12.45 Discussion

12.45 – 13.10 Break

13.10 – 13.20 Venu Gudipati

Chimeric (antibody-based) antigen receptor (CAR) immunotherapy (differences in different CAR generations, CAR T cell therapy in the clinic (+indications), and in development

13.20 – 13.35 Discussion

13.35 – 13.55 Lucas Teuschl

One size fits all cell therapy? MR1-T cells, NK cells, gamma-delta T cells, etc.

13.55 – 14.10 Discussion

14.10 – 14.20 Laura Gebetsberger

Oncolytic virus therapy

14.20 – 14.35 Discussion

14.35 – 14.55 Milena Weber

Future trends in cancer immune therapy (TCR-engineering, combination therapies, nanomedicine-based therapies, mRNA vaccines, etc.)

14.55 – 15.10 Discussion

15.10 – 15.40 Final discussion

Additionally, the following talk will be given at one of the next lab meetings (in February 2022)

Timo Peters

Tumor antigens and immunogenicity: fundamental differences between TCR- and antibody/CAR-mediated recognition, on the role of allelic HLA-variability and other genetic predispositions to recognizing tumor antigens